Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 0.67 |
| ▸ | ALOX5 | P09917 | 5/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | SELP | P16109 | 4/20 | 0.40 |
| ▸ | SELE | P16581 | 2/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.38 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.38 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.38 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CSNK1A1L | Q8N752 | 1/20 | 0.38 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.37 |
| ▸ | GCGR | P47871 | 1/20 | 0.37 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.37 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL719051 | 0.94 | ABCB1 (0.74) | ABCB1ALOX5PTPN1SELPSELE | |
| SCHEMBL30357745 | 0.88 | ABCB1 (0.87) | ABCB1ALOX5PTPN1SELPSELE | |
| SCHEMBL5468480 | 0.87 | ABCB1 (0.89) | ABCB1ALOX5PTPN1SELPSELE | |
| SCHEMBL719050 | 0.81 | ABCB1 (1.00) | ABCB1ALOX5PTPN1SELPSELE | |
| SCHEMBL3826448 | 0.81 | ABCB1 (1.00) | ABCB1ALOX5PTPN1SELPSELE | |
| SCHEMBL3829640 | 0.80 | ABCB1 (0.91) | ABCB1ALOX5PTPN1SELPSELE | |
| SCHEMBL13679717 | 0.80 | ABCB1 (0.91) | ABCB1ALOX5PTPN1SELPSELE | |
| SCHEMBL13679662 | 0.79 | ABCB1 (0.69) | ABCB1ALOX5PTPN1SELPSELE | |
| SCHEMBL13679665 | 0.79 | ABCB1 (0.91) | ABCB1ALOX5MAPK14MAPK11CSNK1A1 | |
| SCHEMBL3824437 | 0.79 | ABCB1 (0.91) | ABCB1ALOX5MAPK14MAPK11CSNK1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070203215-A1 | Methods & Compositions For Enhancing Pharmaceutical Treatments | TAIJI BIOMEDICAL, INC. (US) | 2007-08-30 | — | — | US | disclosed |
| US-20020147197-A1 | Methods and compositions for enhancing pharmaceutical treatments | TAIJI BIOMEDICAL, INC. | 2002-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203215-A1 | Methods & Compositions For Enhancing Pharmaceutical Treatments | TUBB3, TUBB1, TUBB2A | ABCB1 21/4885ALOX5 4407/4885PTPN1 3797/4885 |
| US-20020147197-A1 | Methods and compositions for enhancing pharmaceutical treatments | TUBB3, TUBB1, TUBB2A | ABCB1 14/4885ALOX5 4495/4885PTPN1 3854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.